Newer Biomarkers in Heart Failure

Heart Failure Clinics

Volumn 5, Issue 4, 2009, Pages 579-588

  Gupta, Sachin ^a   Drazner, Mark H ^a   de Lemos, James A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adipokines; Biomarkers; Chromogranin A; Cystatins; Galectins; Heart failure; Osteoprotegerin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; CHROMOGRANIN A; CYSTATIN C; GALECTIN 3; LEPTIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RESISTIN;

DISEASE ASSOCIATION; DISEASE COURSE; HEART FAILURE; HUMAN; OBESITY; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SYMPATHETIC TONE;

ADIPOKINES; BIOLOGICAL MARKERS; CYSTATIN C; GALECTIN 3; HEART FAILURE; HUMANS; OSTEOPROTEGERIN;

EID: 67650588131     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2009.04.004     Document Type: Review

References (53)

1. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
2. Yun T.J., Chaudhary P.M., Shu G.L., et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 161 (1998) 6113-6121
3. Ueland T., Yndestad A., Oie E., et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 111 (2005) 2461-2468
4. Ueland T., Jemtland R., Godang K., et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 44 (2004) 1970-1976
5. Omland T., Drazner M.H., Ueland T., et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 49 (2007) 1392-1398
6. Sharma U.C., Pokharel S., van Brakel T.J., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110 (2004) 3121-3128
7. van Kimmenade R.R., Januzzi Jr. J.L., Ellinor P.T., et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48 (2006) 1217-1224
8. Abrahamson M., Olafsson I., Palsdottir A., et al. Structure and expression of the human cystatin C gene. Biochem J 268 (1990) 287-294
9. Fliser D., and Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 37 (2001) 79-83
10. Ix J.H., Shlipak M.G., Chertow G.M., et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 115 (2007) 173-179
11. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
12. Dries D.L., Exner D.V., Domanski M.J., et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35 (2000) 681-689
13. Ix J.H., Shlipak M.G., Chertow G.M., et al. Cystatin C left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. J Card Fail 12 (2006) 601-607
14. Patel P.C., Ayers C.R., Murphy S.A., et al. Association of ystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail 2 (2009) 98-104
15. Djousse L., Kurth T., and Gaziano J.M. Cystatin C and risk of heart failure in the Physicians' Health Study (PHS). Am Heart J 155 (2008) 82-86
16. Watanabe S., Okura T., Liu J., et al. Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res 26 (2003) 895-899
17. Shlipak M.G., Katz R., Fried L.F., et al. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol 45 (2005) 268-271
18. Lassus J., Harjola V.P., Sund R., et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 28 (2007) 1841-1847
19. Taupenot L., Harper K.L., and O'Connor D.T. The chromogranin-secretogranin family. N Engl J Med 348 (2003) 1134-1149
20. Munoz D.G., Kobylinski L., Henry D.D., et al. Chromogranin A-like immunoreactivity in the human brain: distribution in bulbar medulla and cerebral cortex. Neuroscience 34 (1990) 533-543
21. O'Connor D.T., Kailasam M.T., Kennedy B.P., et al. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 20 (2002) 1335-1345
22. Pieroni M., Corti A., Tota B., et al. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 28 (2007) 1117-1127
23. Wohlschlaeger J., von Winterfeld M., Milting H., et al. Decreased myocardial chromogranin a expression and colocalization with brain natriuretic peptide during reverse cardiac remodeling after ventricular unloading. J Heart Lung Transplant 27 (2008) 442-449
24. Ceconi C., Ferrari R., Bachetti T., et al. Chromogranin A in heart failure: a novel neurohumoral factor and a predictor for mortality. Eur Heart J 23 (2002) 967-974
25. Omland T., Dickstein K., and Syversen U. Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. Am J Med 114 (2003) 25-30
26. Braunwald E. Biomarkers in heart failure. N Engl J Med 358 (2008) 2148-2159
27. Anker S.D., Ponikowski P., Varney S., et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349 (1997) 1050-1053
28. Schulze P.C., and Kratzsch J. Leptin as a new diagnostic tool in chronic heart failure. Clin Chim Acta 362 (2005) 1-11
29. Hopkins T.A., Ouchi N., Shibata R., et al. Adiponectin actions in the cardiovascular system. Cardiovasc Res 74 (2007) 11-18
30. Lawlor D.A., Davey Smith G., Ebrahim S., et al. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 90 (2005) 5677-5683
31. Kistorp C., Faber J., Galatius S., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112 (2005) 1756-1762
32. Tamura T., Furukawa Y., Taniguchi R., et al. Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ J 71 (2007) 623-630
33. Wannamethee S.G., Whincup P.H., Lennon L., et al. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 167 (2007) 1510-1517
34. Kenchaiah S., Evans J.C., Levy D., et al. Obesity and the risk of heart failure. N Engl J Med 347 (2002) 305-313
35. Lavie C.J., Osman A.F., Milani R.V., et al. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol 91 (2003) 891-894
36. Cnop M., Havel P.J., Utzschneider K.M., et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46 (2003) 459-469
37. McEntegart M.B., Awede B., Petrie M.C., et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 28 (2007) 829-835
38. Fruebis J., Tsao T.S., Javorschi S., et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 98 (2001) 2005-2010
39. Ahima R.S., and Flier J.S. Leptin. Annu Rev Physiol 62 (2000) 413-437
40. Doehner W., Pflaum C.D., Rauchhaus M., et al. Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur J Endocrinol 145 (2001) 727-735
41. Doehner W., Rauchhaus M., Godsland I.F., et al. Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha. Int J Cardiol 83 (2002) 73-81
42. Leyva F., Anker S.D., Egerer K., et al. Hyperleptinaemia in chronic heart failure. Relationships with insulin. Eur Heart J 19 (1998) 1547-1551
43. Hintz K.K., Aberle N.S., and Ren J. Insulin resistance induces hyperleptinemia, cardiac contractile dysfunction but not cardiac leptin resistance in ventricular myocytes. Int J Obes Relat Metab Disord 27 (2003) 1196-1203
44. Haynes W.G., Morgan D.A., Walsh S.A., et al. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 100 (1997) 270-278
45. Abe Y., Ono K., Kawamura T., et al. Leptin induces elongation of cardiac myocytes and causes eccentric left ventricular dilatation with compensation. Am J Physiol Heart Circ Physiol 292 (2007) H2387-H2396
46. Barouch L.A., Berkowitz D.E., Harrison R.W., et al. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 108 (2003) 754-759
47. Wolk R., Johnson B.D., and Somers V.K. Leptin and the ventilatory response to exercise in heart failure. J Am Coll Cardiol 42 (2003) 1644-1649
48. Murdoch D.R., Rooney E., Dargie H.J., et al. Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure. Heart 82 (1999) 352-356
49. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-312
50. Patel L., Buckels A.C., Kinghorn I.J., et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 300 (2003) 472-476
51. Azuma K., Katsukawa F., Oguchi S., et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 11 (2003) 997-1001
52. Reilly M.P., Lehrke M., Wolfe M.L., et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111 (2005) 932-939
53. Takeishi Y., Niizeki T., Arimoto T., et al. Serum resistin is associated with high risk in patients with congestive heart failure-a novel link between metabolic signals and heart failure. Circ J 71 (2007) 460-464